NextCure Corp - רווח נקי למניה בארבעת הרבעונים האחרונים NXTC

NextCure, Inc. (NXTC) is deploying its available capital toward costly R&D, which drives the trend of its YoY (ttm) EPS percentage growth. The current level of 64.10 serves as a key metric for this trend. Exclusive FIND patents provide a defensive moat for the business, although strict FDA oversight limits its maneuverability. Meanwhile, geopolitical tensions and sanctions are seriously hindering the international logistics of biomaterials and therapy certification.

This indicator calculates the percentage change in rolling earnings per share over twelve months, eliminating time gaps between quarterly reports to identify real profitability trends. Analyzing the rolling annual growth of net income per share allows for the timely detection of asset overheating, which is critical for NextCure, Inc. (NXTC), as its market capitalization depends on future premium pricing for innovative antibodies.